Best Practices in Lung Cancer – November 2018 Vol 9

Recent Approvals in Immunotherapy Options for Patients with Lung Cancer
Lavinia Dobrea, RN, MS, OCN, Timothy E Byun, MD
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
Immunotherapy drugs work by boosting the immune system so that a person’s own immune system works smarter to identify and destroy any cancer cells.
Use of Immunotherapy Across the Continuum in Non–Small Cell Lung Cancer
Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T)
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
The medical management landscape for non–small cell lung cancer (NSCLC) has been changing with the rapidity of the seasons. Long gone is the day when all are treated equally.
Keeping in Time with Charlotte: Caring for Newly Diagnosed Cancer Patients Who Suffer with Mental Health Comorbidities
Megan A Roy, MSN, RN, OCN,
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
Anyone, regardless of their pre-existing physical or mental health issues, can get cancer.
Treatments in Trial: Lung Cancer Study Updates
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
FDA Grants Priority Review to Application for Pembrolizumab Monotherapy as First-Line Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)
Two New Therapies Active in NSCLC with EGFR/HER2 Exon 20 Mutations
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC).
Entrectinib Encouraging in ROS1-Positive NSCLC
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
Entrectinib achieved high response rates as well as durable responses in patients with ROS1-positive non–small cell lung cancer (NSCLC), including patients with brain metastases, according to a pooled analysis of phase 1 and 2 trials.
New Regimen for SCLC: Atezolizumab plus Chemotherapy
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
Atezolizumab combined with carboplatin/etoposide represents a new standard of care for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), according to results from the phase 3 IMpower133 trial presented at the IASLC 19th World Conference on Lung Cancer.
Next-Generation ALK Inhibitor Prolongs Survival vs Crizotinib in ALK+ NSCLC
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
Brigatinib significantly prolonged survival compared with crizotinib (standard of care) as first-line therapy in patients with advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC).
High Tumor Mutational Burden Predicts Response to Nivolumab plus Ipilimumab Combo in NSCLC
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus stan­dard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).
Home Run: Chemo-Checkpoint Inhibitor Combo in Newly Diagnosed Metastatic NSCLC
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.
Loading More Articles
  • 1
  • 2
Page 1 of 2
Results 1 - 10 of 11

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512